Page 118 - 中国全科医学2022-17
P. 118

http://www.chinagp.net   E-mail:zgqkyx@chinagp.net.cn  ·2163·


               Rheum Dis,2017,76(8):1340-1347. DOI:10.1136/annrheu  2118. DOI:10.3389/fimmu.2018.02118.
               mdis-2016-210322.                               [18]WALLACE D J,FURIE R A,TANAKA Y,et al. Baricitinib for
           [5]VAN DER HEIJDE D,BARALIAKOS X,GENSLER L S,            systemic lupus erythematosus:a double-blind,randomised,
               et al. Efficacy and safety of filgotinib,a selective Janus kinase   placebo-controlled,phase 2 trial[J]. Lancet,2018,392
               1  inhibitor,in  patients  with  active  ankylosing  spondylitis   (10143):222-231. DOI:10.1016/S0140-6736(18)31363-1.
               (TORTUGA):results from a randomised,placebo-controlled,  [19]LI Y P,HIGGS R E,HOFFMAN R W,et al. A Bayesian gene
               phase 2 trial[J]. Lancet,2018,392(10162):2378-2387.   network reveals insight into the JAK-STAT pathway in systemic
               DOI:10.1016/S0140-6736(18)32463-2.                   lupus  erythematosus[J].  PLoS  One,2019,14(12):
           [6]VAN DER HEIJDE D,SONG I H,PANGAN A L,et al. Efficacy   e0225651. DOI:10.1371/journal.pone.0225651.
               and safety of upadacitinib in patients with active ankylosing spondylitis  [20]SHAO W H,SHU D H,ZHEN Y X,et al. Prion-like aggregation
               (SELECT-AXIS 1):a multicentre,randomised,double-blind,  of mitochondrial antiviral signaling protein in lupus patients
               placebo-controlled,phase 2/3 trial[J]. Lancet,2019,394   is associated with increased levels of type   Ⅰ interferon[J].
               (10214):2108-2117. DOI:10.1016/S0140-6736(19)32534-6.  Arthritis Rheumatol,2016,68(11):2697-2707. DOI:
           [7]O'SHEA J J,SCHWARTZ D M,VILLARINO A V,et al. The      10.1002/art.39733.
               JAK-STAT pathway:impact on human disease and therapeutic   [21]ALUNNO A,PADJEN I,FANOURIAKIS A,et al. Pathogenic
               intervention[J]. Annu Rev Med,2015,66:311-328. DOI:  and therapeutic relevance of JAK/STAT signaling in systemic lupus
               10.1146/annurev-med-051113-024537.                   erythematosus:integration of distinct inflammatory pathways and the
           [8]OWEN K L,BROCKWELL N K,PARKER B S. JAK-STAT           prospect of their inhibition with an oral agent[J]. Cells,2019,8
               signaling:a double-edged sword of immune regulation and cancer   (8):E898. DOI:10.3390/cells8080898.
               progression[J]. Cancers,2019,11(12):2002. DOI:  [22]DALBETH N,CHOI H K,JOOSTEN L A B,et al. Gout[J].
               10.3390/cancers11122002.                             Nat Rev Dis Primers,2019,5(1):69. DOI:10.1038/s41572-
           [9]HAMMARÉN H M,VIRTANEN A T,RAIVOLA J,et al. The        019-0115-y.
               regulation of JAKs in cytokine signaling and its breakdown in   [23]SUN Y,ABBONDANTE S,KARMAKAR M,et al. Neutrophil
               disease[J]. Cytokine,2019,118:48-63. DOI:10.1016/j.  caspase-11 is required for cleavage of caspase-1 and secretion
               cyto.2018.03.041.                                    of IL-1β in Aspergillus fumigatus infection[J]. J Immunol,
           [10]MALEMUD C J. The role of the JAK/STAT signal pathway in   2018,201(9):2767-2775. DOI:10.4049/jimmunol.1701195.
               rheumatoid arthritis[J]. Ther Adv Musculoskelet Dis,2018,10  [24]WINKLER  S,RÖSEN-WOLFF  A.  Caspase-1:an  integral
               (5/6):117-127. DOI:10.1177/1759720X18776224.         regulator of innate immunity[J]. Semin Immunopathol,2015,37
           [11]SCHETT G,EMERY P,TANAKA Y,et al. Tapering biologic   (4):419-427. DOI:10.1007/s00281-015-0494-4.
               and conventional DMARD therapy in rheumatoid arthritis:current   [25]TEMMOKU J,FUJITA Y,MATSUOKA N,et al. Uric acid-
               evidence and future directions[J]. Ann Rheum Dis,2016,75(8):  mediated inflammasome activation in IL-6 primed innate immune
               1428-1437. DOI:10.1136/annrheumdis-2016-209201.      cells is regulated by baricitinib[J]. Mod Rheumatol,2021,31(1):
           [12]YOU H X,XU D,ZHAO J L,et al. JAK inhibitors:prospects   270-275. DOI:10.1080/14397595.2020.1740410.
               in connective tissue diseases[J]. Clin Rev Allergy Immunol,  [26]FRANCHIMONT N,WERTZ S,MALAISE M. Interleukin-6:an
               2020,59(3):334-351. DOI:10.1007/s12016-020-08786-6.  osteotropic factor influencing bone formation? [J]. Bone,2005,
           [13]ZHANG A,LEE Y C. Mechanisms for joint pain in rheumatoid   37(5):601-606. DOI:10.1016/j.bone.2005.06.002.
               arthritis(RA):from cytokines to central sensitization[J]. Curr   [27]CHEON Y H,KIM J Y,BAEK J M,et al. WHI-131 promotes
               Osteoporos Rep,2018,16(5):603-610. DOI:10.1007/      osteoblast differentiation and prevents osteoclast formation and
               s11914-018-0473-5.                                   resorption in mice[J]. J Bone Miner Res,2016,31(2):
           [14]BOYDEN  S  D,HOSSAIN  I  N,WOHLFAHRT  A,et  al.      403-415. DOI:10.1002/jbmr.2612.
               Non-inflammatory causes of pain in patients with rheumatoid   [28]XU L J,ZHANG L X,ZHANG H J,et al. The participation
               arthritis[J]. Curr Rheumatol Rep,2016,18(6):30. DOI:  of fibroblast growth factor 23(FGF23)in the progression of
               10.1007/s11926-016-0581-0.                           osteoporosis via JAK/STAT pathway[J]. J Cell Biochem,2018,
           [15]BARAL P,UDIT S,CHIU I M. Pain and immunity:implications   119(5):3819-3828. DOI:10.1002/jcb.26332.
               for host defence[J]. Nat Rev Immunol,2019,19(7):433-  [29]DALAGIORGOU G,PIPERI C,ADAMOPOULOS C,et al.
               447. DOI:10.1038/s41577-019-0147-2.                  Mechanosensor polycystin-1 potentiates differentiation of human
           [16]TAYLOR  P  C,KEYSTONE  E  C,VAN  DER  HEIJDE  D,     osteoblastic cells by upregulating Runx2 expression via induction of
               et al. Baricitinib versus placebo or adalimumab in rheumatoid   JAK2/STAT3 signaling axis[J]. Cell Mol Life Sci,2017,74(5):
               arthritis[J]. N Engl J Med,2017,376(7):652-662. DOI:  921-936. DOI:10.1007/s00018-016-2394-8.
               10.1056/nejmoa1608345.                          [30]JETHWA H,BOWNESS P. The interleukin(IL)-23/IL-17
           [17]CECCHINATO V,D'AGOSTINO G,RAELI L,et al. Redox-      axis in ankylosing spondylitis:new advances and potentials for
               mediated mechanisms fuel monocyte responses to CXCL12/HMGB1   treatment[J]. Clin Exp Immunol,2016,183(1):30-36.
               in active rheumatoid arthritis[J]. Front Immunol,2018,9:  DOI:10.1111/cei.12670.
   113   114   115   116   117   118   119   120   121   122   123